Global Information
회사소개 | 문의 | 위시리스트

세계의 악성 흑색종(MM) 치료제 시장, 용량, 가격, 임상 파이프라인 전망

Global Malignant Melanoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

리서치사 KuicK Research
발행일 2018년 04월 상품 코드 624170
페이지 정보 영문 470 Pages
가격
US $ 3,000 ₩ 3,542,000 Unprintable PDF by E-mail (Single User License)
US $ 3,600 ₩ 4,250,000 CD-ROM
US $ 4,200 ₩ 4,959,000 Hard Copy
US $ 5,000 ₩ 5,904,000 Printable PDF by E-mail (Multi-User License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 악성 흑색종(MM) 치료제 시장, 용량, 가격, 임상 파이프라인 전망 Global Malignant Melanoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024
발행일 : 2018년 04월 페이지 정보 : 영문 470 Pages

세계의 악성 흑색종(MM: Malignant Melanoma) 치료제 시장에 대해 조사 분석했으며, 가격, 용량, 특허, 시장 분석, 기회, 임상 파이프라인 등의 정보를 정리하여 전해드립니다.

제1장 악성 흑색종(MM) : 사망률이 높은 일반암

  • 머리말
  • 위험인자
  • 진단과 치료 개요

제2장 세계의 흑색종 유병률 분석

  • 미국
  • 유럽과 기타 지역의 유병률

제3장 흑색종 시장 분석 : 진단 및 스크리닝별

  • 흑색종 단계 진단과 치료 옵션
  • 흑색종 스크리닝 비용 분석

제4장 악성 흑색종(MM) 치료와 비용 분석 : 단계별

  • 단계 0
  • 단계 I
  • 단계 II 흑색종
  • 단계 III 흑색종
  • 단계 IV 흑색종
  • 재발성 흑색종

제5장 악성 흑색종(MM) 관리와 치료 - 비용 분석 : 치료 방법별

  • 수술
  • 방사선 요법
  • 화학 요법
  • 생물학적 요법/표적 요법
  • 악성 흑색종(MM) 치료에서의 저해제

제6장 세계의 흑색종 치료제 판매 분석

  • 세계 : 흑색종 화학요법 의약품 판매
  • 흑색종 표적요법 매출 분석

제7장 악성 흑색종(MM) 치료 : 시장 동향과 범위 분석

  • 개요 : 스크리닝과 기존 치료 시장
  • 현대 흑색종 치료제 시장

제8장 세계의 악성 흑색종(MM) 치료제 임상 파이프라인 개요

제9장 흑색종 치료제 시장 지역별 분석

  • 북미
  • 유럽
  • 아시아태평양
  • 중동 및 아프리카

제10장 세계의 흑색종 치료제 시장 역학

  • 시장 성장 촉진요인
  • 시장 성장 억제요인

제11장 세계의 악성 흑색종(MM) 치료제 시장에 관한 향후 예측

제12장 세계의 악성 흑색종(MM) 치료제 임상 파이프라인 : 기업별, 상(相)별

  • 단계 불명
  • 연구
  • 전임상
  • 임상
  • 제I상
  • 제I/II상
  • 제II상
  • 제II/III상
  • 제III상
  • 신청완료
  • 승인완료

제13장 출시된 악성 흑색종(MM) 치료제 임상 인사이트

제14장 경쟁 구도

  • AVAX Technologies
  • Biogen Idec
  • BioVex
  • Bristol-Myers Squibb
  • Chiron
  • Enzon Pharmaceuticals
  • GlaxoSmithKline
  • Lorus Therapeutics
  • Medarex
  • Merck
  • Ono Pharmaceutical Co., Ltd.
  • Plexxikon
  • Reliance Life Sciences
  • Roche
LSH 18.04.18

“Global Malignant Melanoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024” report highlights:

  • Global Malignant Melanoma Drug Market Overview
  • Dosage, Price & Patent Insight
  • Global Malignant Melanoma Drug Clinical Pipeline: 197 Drugs
  • Marketed Malignant Melanoma Drug Clinical Insight: 25 Drugs
  • Sales Analysis of Global Melanoma Therapeutics
  • Regional Analysis of the Melanoma Drug Market

Melanoma occurs due to mutations in the skin cells which ultimately lead to the formation of malignant tumors. These tumors commonly originate in the pigment-producing melanocytes in the basal layer of the epidermis. Being an advanced form of skin cancer, it is the cause of maximum number of skin cancer deaths. An insight into the prevalence of melanoma shows a rising trend amplified by the use of tanning beds and increased exposure of skin to ultraviolet rays in regions like the US, Europe & Australia which currently show much higher prevalence than the rest of the world.

Inspite of melanoma being a fatal form of skin cancer, its early detection makes it easily treatable. The melanoma market is flooded with traditional therapeutic approaches of chemotherapy, radiation therapy and surgery with many advanced therapies slowly entering the market. However, each of the traditional method have several limitations; thus leading to an increased need for better and efficient therapeutics.

Current market trends indicate that the malignant melanoma market is slowly shifting to advance and targeted therapeutic methods such as vaccine and immunotherapy. The recent FDA approvals of six biologics within six years has been a boost to the growth of malignant melanoma market with many key players investing heavily on the research and development of therapeutics that have shown promising therapeutic results in clinical studies of malignant melanoma.

The Targeted therapy segment of the malignant melanoma market is anticipated to be the most promising market of the future due to its high efficacy with minimum side effects. Further, sales analysis and future projections of existing therapeutics show exponential growth for the newly introduced biologics like Opdive and cotellic due to multifold increase in adoption rate, positive post marketing response and feedback from users.

The US currently leads the global malignant melanoma market due to large patient base, easy availability and affordability of the newly introduced biologics followed by Europe. Other regions such as Australia and New Zealand have also contributed significantly to the current market size. However, the increasing patient base in highly populated regions like China and India is estimated to shift the market size to these Asian regions by the year 2024.

Overall, the global melanoma market is anticipated to expand in value from US$ close to 5 Billion in 2016 to an estimated US$ 14 billion by 2024, representing a robust Compound Annual Growth Rate (CAGR) of 12%. The advancement in research and development of therapeutics, early entry and dominance of immunotherapeutics, strong investor base and a robust clinical pipeline ensures a bright future for the key players involved in the segment.

KuicK Research report on the global malignant melanoma is based on an in-depth analysis of the current market trends, Opportunities and Other dynamics that may have a significant impact on the market. Special emphasis has been put on the collection and analysis of latest data that will influence the market in the present and the future. Further, analysis of sales data, patent expiry, Cost analysis of therapeutics and collaboration between industries has been used to devise an accurate and efficient projection regarding the future of malignant melanoma market which clearly indicates it to be a key market in the future of skin cancer therapy.

Table of Contents

1. Malignant Melanoma - Common Cancer with High Mortality

  • 1.1. Prologue to Malignant Melanoma
  • 1.2. Risk Factors Associated with Melanoma
  • 1.3. Overview of Melanoma Diagnosis & Therapy

2. Analysis Regarding the Global Prevalence of Melanoma

  • 2.1. Prevalence in the US
  • 2.2. Prevalence in Europe & Rest of the World

3. Melanoma Market Analysis by Diagnosis & Screening

  • 3.1. Stages of melanoma Diagnosis & Treatment Options
  • 3.2. Cost Analysis of Melanoma Screening

4. Malignant Melanoma Therapy & Cost Analysis by Stage

  • 4.1. Stage 0
  • 4.2. Stage I
  • 4.3. Stage II Melanoma
  • 4.4. Stage III Melanoma
  • 4.5. Stage IV Melanoma
  • 4.6. Recurrent Melanoma

5. Malignant Melanoma Management & Therapy - Cost Analysis by Treatment Modality

  • 5.1. Surgery
  • 5.2. Radiation Therapy
  • 5.3. Chemotherapy
    • 5.3.1. Decarbazine
    • 5.3.2. Temozolomide
    • 5.3.3. Taxol (Paclitaxel & Carboplatin)
  • 5.4. Biological Therapy/Targeted Therapies
    • 5.4.1. T-VEC (Imlygic®)
    • 5.4.2. Nivolumab (Opdivo®)
    • 5.4.3. Ipilimumab (Yervoy®)
    • 5.4.4. Pembrolizumab (Keytruda®)
    • 5.4.5. Peginterferon alpha 2-b (Sylatron®)
    • 5.4.6. Interleukin-2(IL-2; Proleukin®)
  • 5.5. Inhibitors in Malignant Melanoma Treatment
    • 5.5.1. Vemurafenib (Zelboraf®) + Cobimetinib (Cotellic®)
    • 5.5.2. Dabrafenib (Tafinlar®) + Trametinib (Mekinist®)
    • 5.5.3. Vemurafenib (Zelboraf®)

6. Sales Analysis of Global Melanoma Therapeutics

  • 6.1. Global- Melanoma Chemotherapy Drug Sales
  • 6.2. Melanoma Targeted Therapy Sales Analysis

7. Malignant Melanoma Therapy - Market Trend & Scope Analysis

  • 7.1. Overview - Screening & Traditional Therapy Market
  • 7.2. Modern Melanoma Therapeutics Market

8. Global Malignant Melanoma Drug Clinical Pipeline Overview

9. Regional Analysis of the Melanoma Drug Market

  • 9.1. North America
    • 9.1.1. US
    • 9.1.2. Canada
  • 9.2. Europe
  • 9.3. Asia Pacific
    • 9.3.1. Japan
    • 9.3.2. China
    • 9.3.3. Australia
  • 9.4. Middle East & Africa (MEA)

10. Global Melanoma Drug Market Dynamics

  • 10.1. Driving Factors of the Malignant Melanoma Drug Market
  • 10.2. Restraining Factors of the Melanoma Drug Market

11. Future Forecast Regarding the Malignant Melanoma Drug Market

12. Global Malignant Melanoma Drug Clinical Pipeline by Company & Phase

  • 12.1. Unknown
  • 12.2. Research
  • 12.3. Preclinical
  • 12.4. Clinical
  • 12.5. Phase-I
  • 12.6. Phase-I/II
  • 12.7. Phase-II
  • 12.8. Phase-II/III
  • 12.9. Phase-III
  • 12.10. Preregistration
  • 12.11. Registered

13. Marketed Malignant Melanoma Drug Clinical Insight

14. Competitive Analysis

  • 14.1. AVAX Technologies
  • 14.2. Biogen Idec
  • 14.3. BioVex
  • 14.4. Bristol-Myers Squibb
  • 14.5. Chiron
  • 14.6. Enzon Pharmaceuticals
  • 14.7. GlaxoSmithKline
  • 14.8. Lorus Therapeutics
  • 14.9. Medarex
  • 14.10. Merck
  • 14.11. Ono Pharmaceutical
  • 14.12. Plexxikon
  • 14.13. Reliance Life Sciences
  • 14.14. Roche

List of Figures

  • Figure 1-1: Historical Timeline of Melanoma
  • Figure 1-2: Malignant Melanoma - Risk Factors
  • Figure 1-3: Difference between Normal Skin Lesions & Melanoma
  • Figure 1-4: Melanoma Development in Action
  • Figure 1-5: Melanoma- Biopsy Types
  • Figure 1-6: Biopsy Techniques used for the Diagnosis of melanoma
  • Figure 2-1: US - Melanoma Prevalence by Gender (Number of patients), 2018
  • Figure 2-2: 5 Year Survival Rate- by Stage of Therapy (%)
  • Figure 2-3: Europe - Regional Mortality by Melanoma (number of Deaths per 100,000 patients), 2012-2016
  • Figure 2-4: Global- Melanoma Prevalence (per 100,000 Individuals), 2016
  • Figure 3-1: Cost Analysis - Melanoma Screening Cost (US$), 2018
  • Figure 3-2: Australia - Melanoma Management & Therapy Cost Analysis (US$/Patient), 2018
  • Figure 4-1: Comparative Price Analysis- by Body Part affected by Melanoma, 2018
  • Figure 4-2: -Melanoma Stage 0 - Estimated Treatment Cost (US$), 2018
  • Figure 4-3: Stage I - Estimated Treatment Cost (US$), 2018
  • Figure 4-4: Melanoma Treatment Efficacy (Stage II) by Treatment Modality (%), 2018
  • Figure 4-5: Stage II -Estimated Cost Analysis by Technique (US$), 2018
  • Figure 4-6: Stage III/IV Treatment Modality Approach
  • Figure 5-1: Surgery-Average Cost Analysis Range by Stage (US$/Patient), 2018
  • Figure 5-2: Surgery - Average Cost Analysis (US$), 2016
  • Figure 5-3: Radiation Therapy - Average Cost Analysis by Melanoma Location (US$), 2018
  • Figure 5-4: Dosage Analysis - Decarbazine & Temozolomide(mg/kg)
  • Figure 5-5: Price Analysis - Decarbazine & Temozolomide(US$/100mg), 2018
  • Figure 5-6: Temozolomide - Price Analysis (US$), 2018
  • Figure 5-7: Temozolomide - Price Analysis (US$/mg), 2018
  • Figure 5-8: Cost Analysis - Melanoma Targeted Therapy (US$/Month), 2018
  • Figure 5-9: T-VEC: Mechanism of Action
  • Figure 5-10:T-VEC- Dosage Analysis(ml/ Plaque Forming Unit*)
  • Figure 5-11: Imlygic - Vial & Therapy Cost Analysis (US$), 2018
  • Figure 5-12: Nivolumab + Iplimumab-Dosage Analysis (mg)
  • Figure 5-13: Yervoy- Mechanism of Action in Melanoma Therapy
  • Figure 5-14: Nivolumab & Ipilimumab- Drug Price Analysis (US$/mg), 2018
  • Figure 5-15: Keytruda -Dosage Analysis (mg/kg)
  • Figure 5-16: Sylatron - Dosage Analysis (mcg/kg body weight/week)
  • Figure 5-17: Interleukin-2 Action Mechanism
  • Figure 5-18: Zelboraf & Cobimetinib - Dosage Analysis (mg)
  • Figure 5-19: Zelboraf & Cotellic - Price Analysis (US$/Month), 2018
  • Figure 5-20: Tafinlar- Dosage Analysis (mg Twice Daily)
  • Figure 5-21: Mekinist - Dosage Analysis (mg once daily)
  • Figure 6-1: Global - Melanoma Chemotherapeutics Sales (US$ Million), 2014-2016
  • Figure 6-2: Global - Melanoma Biological Therapeutics Sales (US$ Million), 2015-2016
  • Figure 7-1: Global - Melanoma Market Segmentation by Diagnosis & Therapy (%), 2018
  • Figure 7-2: Global- Melanoma Diagnosis Market Forecast (US$ Billion), 2016-2024
  • Figure 7-3: Global - Melanoma Chemotherapy Drug Sales Forecast (US$ Billion), 2018-2024
  • Figure 7-4: Global - Melanoma Surgery Market Forecast (US$ Million), 2018-2024
  • Figure 7-5: Global- Radiation Melanoma Therapy Forecast (US$ Million), 2018-2024
  • Figure 7-6: Global - Melanoma Targeted Therapy Market Forecast, 2016-2024
  • Figure 8-1: Global - Malignant Melanoma Pipeline by Phase (%), 2018 till 2024
  • Figure 8-2: Global - Malignant Melanoma Pipeline by Phase (Number), 2018 till 2024
  • Figure 8-3: Global - Malignant Melanoma Pipeline by Phase (%),2018 till 2024
  • Figure 8-4: Global - Malignant Melanoma Pipeline by Phase (Number), 2018 till 2024
  • Figure 9-1: US - Melanoma Therapeutics Market Forecast (US$ Billion), 2016-2024
  • Figure 9-2: Canada- Melanoma Therapeutics Market Forecast (US$ Million), 2016-2024
  • Figure 9-3: Europe - Treatment Modality Used in Melanoma Therapy, 2016-2017
  • Figure 10-1: Driving Factors of the Global Melanoma Drug Market
  • Figure 10-2: Melanoma Drug Market - Growth Restraining Factors

List of Tables

  • Table 3-1: Melanoma Stage, Description & Available Treatment Options
Back to Top
전화 문의
F A Q